Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming.
about
Common stemness regulators of embryonic and cancer stem cellsThe Epigenetic Regulation of Wound HealingValproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in NeuroblastomaRecent technological updates and clinical applications of induced pluripotent stem cellsSuppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells.Small molecules for cell reprogramming and heart repair: progress and perspectiveMicroRNA-26a induced by hypoxia targets HDAC6 in myogenic differentiation of embryonic stem cells.Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and PerspectivesPushing the reset button: chemical-induced conversion of amniotic fluid stem cells into a pluripotent stateReprogramming adult human dermal fibroblasts to islet-like cells by epigenetic modification coupled to transcription factor modulation.Histone modification of embryonic stem cells produced by somatic cell nuclear transfer and fertilized blastocysts.Glucocorticoid receptor and Histone deacetylase 6 mediate the differential effect of dexamethasone during osteogenesis of mesenchymal stromal cells (MSCs).The SIN3A/HDAC Corepressor Complex Functionally Cooperates with NANOG to Promote Pluripotency.Migration, proliferation, and differentiation of cord blood mesenchymal stromal cells treated with histone deacetylase inhibitor valproic Acid.Prospects and challenges of reprogrammed cells in hematology and oncology.Histone deacetylase inhibitors: a patent review (2009 - 2011).Unique functional roles for class I and class II histone deacetylases in central nervous system development and function.Generation of functional hepatic cells from pluripotent stem cells.Therapeutical Strategies for Spinal Cord Injury and a Promising Autologous Astrocyte-Based Therapy Using Efficient Reprogramming Techniques.Repressors of reprogramming.Histone Deacetylase Inhibitors as Anticancer Drugs.Reprogramming Enhancers in Somatic Cell Nuclear Transfer, iPSC Technology, and Direct Conversion.Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1Histone deacetylase (HDAC) inhibitors down-regulate endothelial lineage commitment of umbilical cord blood derived endothelial progenitor cells.Epigallocatechin-3-gallate enhances differentiation of acute promyelocytic leukemia cells via inhibition of PML-RARα and HDAC1.The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.Evaluation of developmental toxicity using undifferentiated human embryonic stem cells.The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism.Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
P2860
Q26777882-98A4C662-2E5D-4ACE-B936-250862F53A5DQ26827395-A5F71654-766A-46B5-9595-2CCF095ADC9FQ28554068-E6349F19-DD24-4EEC-94EE-276E46D2916AQ34184553-596E146E-9621-4ECC-8CAC-838A580CA85EQ34623528-0887A576-9D2D-455F-8D8F-9DD1398BDE79Q35076609-FB54DFF2-E40D-4422-A894-128443389307Q35131168-E1636B5B-4A6E-4BCB-9CC7-E0E0AFCF1260Q35744910-5534BBE7-D166-420A-A797-E07BC8CABD50Q36298670-BBCDB130-33C9-4A63-B177-59030AC29112Q37139609-F3178227-B32A-4D1F-BC61-1DC6854A12D4Q37400043-49B957B0-D6A0-422F-BD4E-F18D66A6AD29Q37453914-3E7ABCAD-1CAA-443A-84E6-ED1AC9A96C7CQ37669332-987DFC2B-CC53-4F24-BA84-23F2EF4F2A17Q37686598-91E72D60-0440-482E-BB40-BC25CA5BC160Q38031618-BCBBF884-B345-4D33-8E8D-751518FC29AAQ38055210-308FC5A4-88F8-4A79-A91F-24858E0B02F4Q38087145-BA156ED9-4043-4A94-B2B0-CD42F7157FCCQ38264448-DC2CCF57-14CF-4D66-A298-16BB29B6148FQ38416280-38DDD0FD-CE5F-499C-990D-81CA09A78300Q38443588-271F7360-0B34-4226-86B2-5B40C6B28C8AQ38696932-84796855-463C-4F01-BA1C-ED4BB2D54CA4Q38798149-0A3453EC-491C-49CA-8157-CA2A97C682B4Q41882369-F5622F5A-CD28-4548-8422-9194CFE4E10AQ42366379-DE933E58-4BF6-4937-9EB0-B4F660B8B320Q47343544-50A47DB4-713E-492E-96D0-0A871CE8A3C4Q48303460-1EAB4388-9479-4F48-8FC3-33CB6A315BAFQ50670102-4EB681F6-C0B8-44C8-A686-88E29F6A3C8BQ51584888-2887F502-5739-4D71-84B2-6A0DC831570FQ55485574-6340E165-16C7-40FC-B97C-50D85D65EF4CQ58792448-D09204CA-ED8C-4C9D-9A2A-3AE92A0B64D3
P2860
Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming.
@en
type
label
Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming.
@en
prefLabel
Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming.
@en
P2093
P2860
P356
P1476
Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming.
@en
P2093
Androniki Kretsovali
Christiana Hadjimichael
Nikolaos Charmpilas
P2860
P304
P356
10.1155/2012/184154
P577
2012-03-08T00:00:00Z